1361227-90-8
1361227-90-8 structure
- Name: JH-RE-06
- Chemical Name: JH-RE-06
- CAS Number: 1361227-90-8
- Molecular Formula: C20H16Cl3N3O4
- Molecular Weight: 468.72
- Catalog: Signaling Pathways Cell Cycle/DNA Damage DNA/RNA Synthesis
- Create Date: 2019-08-03 18:26:59
- Modify Date: 2024-01-11 16:30:49
-
JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 sensitizes mouse and human cell lines to Cisplatin, and suppresses tumor progression in mice and prolongs animal survival[1].
| Name | JH-RE-06 |
|---|
| Description | JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 sensitizes mouse and human cell lines to Cisplatin, and suppresses tumor progression in mice and prolongs animal survival[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.78 μM (REV1-REV7)[1] Kd: 0.42 μM (REV1-REV7)[1] |
| In Vitro | JH-RE-06 unexpectedly induces dimerization of the REV1 CTD at its REV7-binding surface and blocks the REV1-REV7 interaction[1]. |
| In Vivo | JH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines[1]. Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice[1]. |
| References |
| Molecular Formula | C20H16Cl3N3O4 |
|---|---|
| Molecular Weight | 468.72 |